Consistent with our results, previous study also suggested that ACE2 expression was reduced in breast cancer 27, non-small cell lung cancer 28, pancreatic cancer 29 and hepatocellular carcinoma 30, and healthy individuals have increased serum ACE2 activity 31. This evidence concerns the gene ACE2 and hepatocellular carcinoma.